ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen

Show other versions (1)

Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel...

Full description

Bibliographic Details
Main Authors: Anieta M. Sieuwerts, Márcia A. Inda, Marcel Smid, Henk van Ooijen, Anja van de Stolpe, John W. M. Martens, Wim F. J. Verhaegh
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
signaling pathway
functional activity
metastasis
progression-free survival
tamoxifen
treatment response
Online Access:https://www.mdpi.com/2072-6694/12/4/802

Internet

https://www.mdpi.com/2072-6694/12/4/802

Similar Items